Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Ebdarokimab (AK101) in Moderate-to-severe Plaque Psoriasis
NCT05120297Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2021
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing AK101 with Placebo (2 arms). Primary endpoints: Percentage of subjects achieving >= 75% reduction in PASI score at 16 weeks and Percentage of subjects achieving sPGA clearance or very slight (0/1) at 16 weeks. Started Nov 2021; status: completed.
02
Drugs
ebdarokimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05120297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05120297.